CEO Stories: Keeping an eye on Oculogica

Until now, diagnosis of concussion has been highly subjective, and tests that rely on a baseline evaluation may be unreliable because people can “game” their results through memorization.

ADDITIONAL APPLICATIONS

The eye-movement technology on which the EyeBox was based was developed by Dr. Uzma Samadani in 2011; sister of CEO Rosina Samadani, a former management consultant who joined Oculogica as CEO in 2015. According to Rosina, who has a Ph.D. in biomedical engineering, the eye-movement-tracking technology could have other applications and will likely be the foundation for additional devices. The next hurdle: getting it to a price point where it can be widely used.

GAME CHANGER

Oculogica has caught the eye of professional sports leagues as well as team doctors. Given that the leagues tend to favor baseline tests, the EyeBox could be a game changer in diagnosis and treatment. However, potential uses go beyond athletes: sports injuries account for only 18 percent of concussions. Rosina estimates the market as being in excess of $1 billion. In October of 2018, Oculogica was honored by the Angel Capital Association with its Louis Villalobos Award for “outstanding ingenuity, creativity, and innovation.”